BR112016012141A2 - "combinações farmacêuticas, uso das mesmas, e embalagem comercial" - Google Patents

"combinações farmacêuticas, uso das mesmas, e embalagem comercial"

Info

Publication number
BR112016012141A2
BR112016012141A2 BR112016012141A BR112016012141A BR112016012141A2 BR 112016012141 A2 BR112016012141 A2 BR 112016012141A2 BR 112016012141 A BR112016012141 A BR 112016012141A BR 112016012141 A BR112016012141 A BR 112016012141A BR 112016012141 A2 BR112016012141 A2 BR 112016012141A2
Authority
BR
Brazil
Prior art keywords
cancer
combination
pharmaceutical
commercial packaging
pyridin
Prior art date
Application number
BR112016012141A
Other languages
English (en)
Inventor
Hirawat Samit
Massacesi Cristian
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112016012141A2 publication Critical patent/BR112016012141A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMBINAÇÕES FARMACÊUTICAS, USO DAS MESMAS, E EMBALAGEM COMERCIAL. A presente invenção refere-se a uma combinação farmacêutica contendo: (a) um inibidor de fosfatidilinositol-3-cinase selecionado entre 5-(2,6-di-morfolin-4-il-pirimidin-4-il)-4-trifluorometil-piridin-2-ilamina, 2-amida 1-({4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il}-amida) de ácido (S)-Pirrolidina-1,2-dicarboxílico ou qualquer sal farmaceuticamente aceitável dos mesmos e (b) um agonista de gonadorelina e, opcionalmente, (c) um agente antiestrogênio, particularmente para uso no tratamento ou prevenção de um câncer; usos dessa combinação na preparação de um medicamento para o tratamento ou prevenção de um câncer; composições farmacêuticas da combinação dos referidos agentes terapêuticos e métodos de tratamento de um câncer em um paciente compreendendo administrar ao referido paciente um montante terapeuticamente eficaz dessa combinação.
BR112016012141A 2014-01-15 2015-01-13 "combinações farmacêuticas, uso das mesmas, e embalagem comercial" BR112016012141A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14305057 2014-01-15
PCT/IB2015/050260 WO2015107461A1 (en) 2014-01-15 2015-01-13 Pharmaceutical combinations

Publications (1)

Publication Number Publication Date
BR112016012141A2 true BR112016012141A2 (pt) 2017-08-08

Family

ID=50033443

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016012141A BR112016012141A2 (pt) 2014-01-15 2015-01-13 "combinações farmacêuticas, uso das mesmas, e embalagem comercial"

Country Status (11)

Country Link
US (2) US20160331755A1 (pt)
EP (1) EP3094340A1 (pt)
JP (2) JP2017502989A (pt)
KR (1) KR20160101027A (pt)
CN (2) CN105916515A (pt)
AU (2) AU2015207723A1 (pt)
BR (1) BR112016012141A2 (pt)
CA (1) CA2936783A1 (pt)
MX (1) MX2016009226A (pt)
RU (2) RU2020121929A (pt)
WO (1) WO2015107461A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210000815A1 (en) * 2017-12-28 2021-01-07 Constellation Pharmaceuticals, Inc. Pharmacokinetic enhancement of ezh2 inhibitors through combination therapies
WO2023150267A1 (en) * 2022-02-03 2023-08-10 Maison Amori Oqvpo Llc Methods, compositions and uses for treating cancer by providing medications that induce targeted tumor cell mitosis before providing chemotherapy or radiation and kits therefor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
MX2007008809A (es) * 2005-01-21 2007-09-07 Astex Therapeutics Ltd Combinaciones de inhibidores de pirazol cinasa y otros agentes antitumor.
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
CN101019828A (zh) * 2007-03-23 2007-08-22 济南帅华医药科技有限公司 一种含磷酸肌醇3－激酶抑制剂及激素类药物的抗癌组合物
AU2008250328A1 (en) * 2007-05-09 2008-11-20 Novartis Ag Substituted imidazopyridazines as PI3K lipid kinase inhibitors
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
WO2011130342A1 (en) * 2010-04-14 2011-10-20 Incyte Corporation FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
EP2592933B1 (en) * 2010-07-16 2017-04-05 Anderson Gaweco Mif inhibitors and their uses
KR20140072028A (ko) * 2011-08-31 2014-06-12 노파르티스 아게 Pi3k- 및 mek-억제제의 상승작용적 조합물
US20150023954A1 (en) * 2012-03-23 2015-01-22 Memorial Sloan-Kettering Cancer Center Potentiating antibody-induced complement-mediated cytotoxicity via pi3k inhibition
US20150148345A1 (en) * 2013-11-26 2015-05-28 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders

Also Published As

Publication number Publication date
US20170304311A1 (en) 2017-10-26
AU2017245302A1 (en) 2017-11-02
RU2020121929A (ru) 2020-07-13
CA2936783A1 (en) 2015-07-23
JP2020023497A (ja) 2020-02-13
AU2017245302B2 (en) 2019-04-04
EP3094340A1 (en) 2016-11-23
AU2015207723A1 (en) 2016-06-09
JP2017502989A (ja) 2017-01-26
RU2016133285A3 (pt) 2018-08-28
KR20160101027A (ko) 2016-08-24
US10085996B2 (en) 2018-10-02
WO2015107461A1 (en) 2015-07-23
US20160331755A1 (en) 2016-11-17
CN105916515A (zh) 2016-08-31
RU2016133285A (ru) 2018-02-20
MX2016009226A (es) 2016-10-05
CN112535688A (zh) 2021-03-23

Similar Documents

Publication Publication Date Title
BR112015030578A2 (pt) combinações farmacêuticas
CL2023000848A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
BR112017017009A2 (pt) usos de um sequestrante de formaldeído e de uma composição farmacêutica, métodos para impedir, adiar, retardar ou diminuir a transformação de um composto e para tratar câncer, e, composição farmacêutica.
MX2019012884A (es) Terapia de combinacion.
BR112014028633A8 (pt) tratamento de amd usando sflt-1 de aav
HRP20220718T1 (hr) Kombinacijska terapija uključujući inhibitor mdm2 i jedan ili više dodatnih farmaceutski aktivnih sredstava za liječenje raka
BR112020019875A8 (pt) composições tópicas para alívio da dor
BR112015018252A2 (pt) composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit
EP4218816A3 (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
MX2021001807A (es) Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.
MX2014002471A (es) Combinaciones sinergicas de los inhibidores de p13k y mek.
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
AR088585A1 (es) Un medicamento para tratar la enfermedad del ojo anterior
BR112015001212A2 (pt) terapia de combinação de inibidores de igf1 r e pi3k
WO2015035410A8 (en) Cancer therapy
TN2016000498A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine.
AR098832A1 (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
CL2011000805A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion de lictus en pacientes que padecen fibrilacion auricular.
BR112016012141A2 (pt) "combinações farmacêuticas, uso das mesmas, e embalagem comercial"
BR112015030664A2 (pt) combinação farmacêutica de um inibidor de pi3k e um agente desestabilizador de microtúbulos
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
AR107935A1 (es) Uso del compuesto 6-(4-(2,3-dimetilfenoxi)piperidin-1-il)metil)pirimidino-2,4(1h,3h)-diona o una sal farmacéuticamente aceptable del mismo para preparar un medicamento, combinación y composición farmacéutica que comprende dicho compuesto
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
BR112015012497A8 (pt) combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial
BR112016014903A8 (pt) combinações farmacêuticas que compreendem um inibidor de pi3k, seu uso, sua preparação combinada, e embalagem comercial

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements